查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1612200

抗菌藥物抗藥性監測市場：按組件、最終用戶分類 - 2025-2030 年全球預測

Antimicrobial Resistance Surveillance Market by Component (Diagnostic Kits, Diagnostic Systems, Services), End-User (Hospitals, Research & Academic Institutes) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗菌藥物抗藥性監測市場價值為56億美元，預計到2024年將達到59.6億美元，複合年成長率為6.49%，預計到2030年將達到87.1億美元。

抗菌素抗藥性 (AMR) 監測是指系統收集、分析和解釋與病原體中抗菌素抗藥性的盛行率和模式相關的資料。需要這項重要的公共衛生工具來監測抗藥性如何傳播，指導抗生素的使用，並為新藥和治療通訊協定的開發提供資訊。抗菌素抗藥性監測適用於整個醫療機構、社區環境和國家衛生系統，最終用戶包括醫院、診斷實驗室、研究機構、製藥公司和政府機構。該領域的市場成長受到以下因素的推動：抗藥性感染疾病的日益流行、由於有效選擇耗盡而對新型抗生素的迫切需求，以及政府的支持性政策以及全球強調協調一致的抗微生物藥物抗藥性策略的努力。快速診斷測試等技術進步以及公共和私營部門研發資金的增加帶來了巨大的機會。此外，人工智慧和巨量資料分析提供了創新和先進調查方法的潛力。然而，這個市場面臨著挑戰​​，例如與新診斷技術相關的高成本以及資源匱乏地區的專業知識有限，這些都是採用的障礙。此外，由於國家標準和監測能力不同而導致資料不一致，使全球努力變得複雜。為了實現業務成長，創新應專注於提高快速診斷的成本效益和可及性、利用人工智慧進行預測建模以及擴大即時檢測。與國際衛生組織的持續合作也提供了策略優勢。市場動態是動態的，反映了對解決方案的迫切需求，相關人員優先考慮適應、跨境合作和創新技術的整合，以克服快速發展的微生物威脅。

主要市場統計
基準年[2023] 56億美元
預計年份 [2024] 59.6億美元
預測年份 [2030] 87.1億美元
複合年成長率（%） 6.49%

市場動態：快速發展的抗菌藥物抗藥性監測市場的關鍵市場洞察

供需的動態交互作用正在改變抗菌藥物抗藥性監測市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 病原體引起的感染疾病增加
    • 政府採取更多措施來提高診斷和照護現場診斷的質量
  • 市場限制因素
    • 與抗菌藥物抗藥性監測相關的高成本
  • 市場機會
    • 對管理抗菌素抗藥性 (AMR) 感染的先進診斷解決方案的需求不斷成長
    • 全球診斷藥物核准量增加
  • 市場挑戰
    • 缺乏抗菌素抗藥性監測的標準化方法和指南

波特的五力：駕馭抗菌藥物抗藥性監測市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗菌藥物抗藥性監測市場的外部影響

外部宏觀環境因素在塑造抗菌素抗藥性監測市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解抗菌藥物抗藥性監測市場的競爭格局

抗菌素抗藥性監測市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣抗菌藥物抗藥性監測市場供應商的績效評估

FPNV 定位矩陣是評估抗菌藥物抗藥性監測市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為抗菌藥物抗藥性監測市場的成功指明道路

對於旨在加強其在全球市場的影響力的公司來說，抗菌素抗藥性監測市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 病原體引起的感染疾病傳播增加
      • 政府加大力度提高診斷和照護現場診斷的質量
    • 抑制因素
      • 與抗菌藥物抗藥性監測相關的高成本
    • 機會
      • 對管理抗菌素抗藥性 (AMR)感染疾病的先進診斷解決方案的需求不斷成長
      • 全球診斷產品的監管核准數量增加
    • 任務
      • 缺乏抗菌素抗藥性監測的標準化方法和指南
  • 市場區隔分析
    • 組件：診斷試劑套件在以相對較低的成本快速檢測特異性抗性標記物方面發揮重要作用
    • 最終用戶：醫院感染發生率的增加推動了對下一代抗菌素抗藥性 (AMR) 監測的需求。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章抗菌藥物抗藥性監測市場：依組成部分

  • 診斷套件
  • 診斷系統
  • 服務
  • 軟體

第7章 抗菌藥物抗藥性監測市場：依最終用戶分類

  • 醫院
  • 研究/學術機構

第8章美洲抗菌藥物抗藥性監測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區抗菌藥物抗藥性監測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲抗菌藥物抗藥性監測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • AI 驅動的 AMRx 工具用於先進的抗菌藥物抗藥性診斷和治療，提高準確性和患者治療效果
    • Visbee Medical 獲得 180 萬美元資金，用於推進具有抗生素抗藥性篩檢功能的可攜式淋病檢測
    • Novo Holdings 收購 Paratech Pharmaceuticals 以加強對抗抗藥性感染疾病的鬥爭
    • AMR行動基金擴大對抗抗生素抗藥性的投資
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • acquired by bioMerieux SA
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bruker Corporation
  • Cepheid by Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Hologic, Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services Inc.
  • Liofilchem Srl
  • Luminex Corporation by DiaSorin SpA
  • Merck & Co., Inc.
  • Novo Holdings A/S
  • OpGen, Inc.
  • Pfizer Inc.
  • QIAGEN GmbH
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Venatorx Pharmaceuticals, Inc.
  • Viatris Inc.
  • Vivli Inc.
  • Wolters Kluwer NV
Product Code: MRR-CF6C60CF95A8

The Antimicrobial Resistance Surveillance Market was valued at USD 5.60 billion in 2023, expected to reach USD 5.96 billion in 2024, and is projected to grow at a CAGR of 6.49%, to USD 8.71 billion by 2030.

Antimicrobial resistance (AMR) surveillance refers to the systematic collection, analysis, and interpretation of data related to the prevalence and patterns of antimicrobial resistance in pathogens. This critical public health tool is necessary to monitor how resistance is spreading, to guide the use of antimicrobial agents, and to inform on the development of new drugs and treatment protocols. AMR surveillance is applied within healthcare facilities, community settings, and through national health systems, with an end-user scope that includes hospitals, diagnostic labs, research institutes, pharmaceutical companies, and governmental bodies. Market growth in this field is influenced by the increasing prevalence of drug-resistant infections, the urgent need for novel antimicrobials due to the depletion of effective options, and supportive government policies alongside global initiatives that emphasize collaborative strategies against AMR. Technological advancements, like rapid diagnostic tests, and increased funding for R&D by both public and private sectors present significant opportunities. Additionally, AI and big data analytics are offering potential avenues for innovation, driving forward surveillance methodologies. However, the market faces challenges, including high costs associated with novel diagnostic technologies and limited expertise in low-resource settings, which represents a barrier to widespread implementation. Furthermore, discrepancies in data due to varying standards and surveillance capacities across nations complicate global efforts. For business growth, innovation should focus on enhancing cost-effectiveness and accessibility of rapid diagnostics, exploiting AI for predictive modeling, and expanding point-of-care testing. Continuous collaboration with international health organizations can also provide strategic advantages. The market's nature is dynamic, reflecting an urgent demand for solutions, pushing stakeholders to prioritize adaptation, cross-border collaboration, and the integration of innovative technologies that can outpace rapidly evolving microbial threats.

KEY MARKET STATISTICS
Base Year [2023] USD 5.60 billion
Estimated Year [2024] USD 5.96 billion
Forecast Year [2030] USD 8.71 billion
CAGR (%) 6.49%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antimicrobial Resistance Surveillance Market

The Antimicrobial Resistance Surveillance Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of infections caused by pathogens
    • Rising government initiatives to improve the quality of diagnostics and point-of-care diagnosis
  • Market Restraints
    • High cost associated with antimicrobial resistance surveillance
  • Market Opportunities
    • Growing demand for advanced diagnostic solutions to manage Antimicrobial Resistance (AMR) infections
    • Increasing regulatory approvals of diagnostics products worldwide
  • Market Challenges
    • Lack of standardized methods and guidelines for AMR surveillance

Porter's Five Forces: A Strategic Tool for Navigating the Antimicrobial Resistance Surveillance Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antimicrobial Resistance Surveillance Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antimicrobial Resistance Surveillance Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antimicrobial Resistance Surveillance Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antimicrobial Resistance Surveillance Market

A detailed market share analysis in the Antimicrobial Resistance Surveillance Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antimicrobial Resistance Surveillance Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antimicrobial Resistance Surveillance Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antimicrobial Resistance Surveillance Market

A strategic analysis of the Antimicrobial Resistance Surveillance Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antimicrobial Resistance Surveillance Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accelerate Diagnostics, Inc., acquired by bioMerieux SA, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMerieux SA, Bruker Corporation, Cepheid by Danaher Corporation, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Hologic, Inc., Illumina, Inc., Johnson & Johnson Services Inc., Liofilchem S.r.l., Luminex Corporation by DiaSorin S.p.A., Merck & Co., Inc., Novo Holdings A/S, OpGen, Inc., Pfizer Inc., QIAGEN GmbH, Sanofi S.A., Thermo Fisher Scientific Inc., Venatorx Pharmaceuticals, Inc., Viatris Inc., Vivli Inc., and Wolters Kluwer N.V..

Market Segmentation & Coverage

This research report categorizes the Antimicrobial Resistance Surveillance Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Diagnostic Kits, Diagnostic Systems, Services, and Software.
  • Based on End-User, market is studied across Hospitals and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of infections caused by pathogens
      • 5.1.1.2. Rising government initiatives to improve the quality of diagnostics and point-of-care diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with antimicrobial resistance surveillance
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing demand for advanced diagnostic solutions to manage Antimicrobial Resistance (AMR) infections
      • 5.1.3.2. Increasing regulatory approvals of diagnostics products worldwide
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standardized methods and guidelines for AMR surveillance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: Significant role of diagnostic kits in offering rapid detection of specific resistance markers at relatively lower costs
    • 5.2.2. End-User: Increasing incidence of hospital-acquired infections developed necessities for next generation antimicrobial resistance (AMR) surveillance
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antimicrobial Resistance Surveillance Market, by Component

  • 6.1. Introduction
  • 6.2. Diagnostic Kits
  • 6.3. Diagnostic Systems
  • 6.4. Services
  • 6.5. Software

7. Antimicrobial Resistance Surveillance Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Research & Academic Institutes

8. Americas Antimicrobial Resistance Surveillance Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Antimicrobial Resistance Surveillance Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Antimicrobial Resistance Surveillance Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. AI-Driven AMRx Tool Advanced Antimicrobial Resistance Diagnosis and Treatment, Enhancing Accuracy and Patient Outcomes
    • 11.3.2. Visby Medical Secures USD 1.8 Million to Advance Portable Gonorrhea Test with Antibiotic Resistance Screening
    • 11.3.3. Novo Holdings Strengthens Fight Against Drug-Resistant Infections by Acquiring Paratek Pharmaceuticals
    • 11.3.4. AMR Action Fund Expands Investment Efforts to Tackle Antibiotic Resistance
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Accelerate Diagnostics, Inc.
  • 3. acquired by bioMerieux SA
  • 4. Agilent Technologies, Inc.
  • 5. Becton, Dickinson and Company
  • 6. bioMerieux SA
  • 7. Bruker Corporation
  • 8. Cepheid by Danaher Corporation
  • 9. F. Hoffmann-La Roche Ltd
  • 10. GlaxoSmithKline PLC
  • 11. Hologic, Inc.
  • 12. Illumina, Inc.
  • 13. Johnson & Johnson Services Inc.
  • 14. Liofilchem S.r.l.
  • 15. Luminex Corporation by DiaSorin S.p.A.
  • 16. Merck & Co., Inc.
  • 17. Novo Holdings A/S
  • 18. OpGen, Inc.
  • 19. Pfizer Inc.
  • 20. QIAGEN GmbH
  • 21. Sanofi S.A.
  • 22. Thermo Fisher Scientific Inc.
  • 23. Venatorx Pharmaceuticals, Inc.
  • 24. Viatris Inc.
  • 25. Vivli Inc.
  • 26. Wolters Kluwer N.V.

LIST OF FIGURES

  • FIGURE 1. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, FPNV POSITIONING MATRIX, 2023